RNA interference (RNAi) offers a promising therapeutic approach for dominant genetic disorders that involve gain-of-function mechanisms. One candidate disease for RNAi therapy application is myotonic dystrophy type 1 (DM1), which results from toxicity of a mutant mRNA. DM1 is caused by expansion of a CTG repeat in the 3′ UTR of the DMPK gene. The expression of DMPK mRNA containing an expanded CUG repeat (CUG exp ) leads to defects in RNA biogenesis and turnover. We designed miRNAbased RNAi hairpins to target the CUG exp mRNA in the human α-skeletal muscle actin long-repeat (HSA LR ) mouse model of DM1.
Introduction
A direct approach for treating autosomal dominant gain-of-function genetic disease is inhibition or downregulation of expression of the dominant-acting gene product. For myotonic dystrophy (DM), the molecular effector is a mutant mRNA carrying an expressed DNA repeat, either a CTG repeat from the dystrophia myotonica-protein kinase gene (DMPK; type 1 [DM1]) or an expanded CCTG repeat expressed from intron 1 of the CCHC-type zinc finger nucleic acid binding protein gene (CNBP; type 2 [DM2]) (1) (2) (3) (4) . The expanded repeat regions do not result in protein mutation because they are located in the 3′ UTR and intronic pre-mRNA, respectively, but lead to nuclear transcript accumulation that affects the localization and activities of RNA-binding proteins, including the muscleblind-like proteins (MBNLs) and the CELF protein CUGBP1 (5) (6) (7) (8) (9) . MBNL proteins regulate alternative splicing of a subset of mRNAs, and their CUG exp binding and high level of sequestration in DM nuclear foci contributes to the wide-ranging manifestations of disease, such as delayed muscle relaxation (myotonia), insulin insensitivity, muscle weakness and cardiac arrhythmias (10) (11) (12) [reviewed in (13, 14) ]. CELF proteins have been directly linked to DM muscle phenotypes through missplicing of the insulin receptor and the muscle-specific chloride channel mRNAs (15) . Additionally, upregulation of CUGBP1 in mice reproduces some features of DM, including muscle wasting, and knockout mice show improved muscle histopathology (16, 17 (19) . Consistent with the DM phenotype, the HSA LR mouse also displays robust myotonia and pronounced pre-mRNA splicing changes, although muscle wasting and weakness are less severe (20) . The explanation for this discrepancy is unknown, but may relate to differences in developmental expression (later onset in mice) and size of the repeat tract (220 repeats versus >3000 in DM1 patients) (21) . In terms of developing a whole-body treatment for DM1, the deficiency of the HSA LR mouse model is the lack of a multisystem phenotypic representation of the human condition due to muscle-specific expression of the CUG exp mRNA. Therefore, the HSA LR mouse, as a muscle-specific disease model, provides a platform for developing strategies targeting a widespread and abundant tissue, but does not allow for evaluation of therapeutic efficacy for disease complications in motor neurons and other organs. Several groups have used antisense oligonucleotide (ASO) strategies in the HSA LR mouse for mitigation of phenotypic effects in muscle as a proof of principle (19, (22) (23) (24) . These studies served to validate CUG exp mRNA targeting as a route to therapeutic intervention. We explored whether systemic recombinant adeno-associated viral (rAAV) vector delivery of RNA interference (RNAi) expression cassettes could be applied to silence the nuclear CUG exp mRNA in the HSA LR mouse model of DM1, leading to a long-term treatment. RNAi is an evolutionarily conserved cellular process that functions in host-virus defense and in regulating gene expression through post-transcriptional gene silencing (25, 26) . Early in vivo studies in the liver indicated that some toxicities were associated with AAV short hairpin RNAs (shRNAs) due to oversaturation of Argonaute 2 (Ago2), the siRNA duplex guide strand binding protein in the RNA-induced silencing complex (27, 28) . However, development of safer RNAi scaffolds, based on microRNA (miRNA) hairpins, has had a significant impact on RNAi in vivo applications (29) (30) (31) . Administration of therapeutic RNAi to non-human primates and patients has shown success in recent studies of infection, cancer, neurological and metabolic liver disease (32) . rAAV was recently approved as a commercial drug delivery vehicle for lipoprotein lipase deficiency (33) . We demonstrated previously that RNAi silencing of a cytoplasmic mRNA via systemic delivery of a rAAV vector was effective at reducing histological, biochemical, immunological and functional disease features in skeletal muscles of an FRG1 overexpressing transgenic mouse model of facioscapulohumeral muscular dystrophy (34) . In a separate study of the FRG1 mouse, intramuscular injection of rAAV-delivered RNA hairpins prevented FRG1 phenotype development in the TA muscles (35) . Although RNAi is believed to function mainly in the cytoplasm, studies of nuclear expressed shRNAs in cells in vitro have shown that RNAi can reduce levels of nuclear 7SK and U6 snRNAs (36) . In addition, studies demonstrated that shRNAs could reduce the level of nuclear-retained, mutant DMPK mRNA in DM1 cells in vitro (37) . We therefore explored whether a nuclear localized CUG exp mRNA could be reduced using rAAV-mediated systemic delivery of therapeutic RNAi. To test this possibility, we applied systemic RNAi delivery in the HSA LR mouse model of DM using the muscle-tropic rAAV serotype 6 (rAAV6) (38) . We chose the HSA LR mouse model because it was the most disease representative model that was well characterized and available for study, anticipating that the DMPK mRNA is accessible because of successful viral-mediated RNAi silencing in DM1 patient cells (37 target sequences within the HSA mRNA were chosen based on established design rules, and excluded regions that were homologous with the mouse Acta1 mRNA sequence (39) (40) (41) (42) . For in vitro testing of the HSA shRNAs, the HSA gene cDNA sequence was cloned downstream of firefly luciferase (Luc; Fig. 1A ). Candidate HSA shRNAs were expressed from the mouse U6 (mU6) promoter and compared for knockdown efficiency in a co-transfection assay in COS-1 cells. Controls for knockdown efficiency were plasmids lacking an shRNA sequence or expressing a β-galactosidase (β-gal) shRNA. HSA mRNA reduction ranged from 55 to 88% of control levels. From the 16 shRNA target sequences, two were chosen for testing in vivo based on their differing locations either in the coding sequence or in the 3′ UTR where miRNAs typically bind for translational repression. Based on mRNA target regions known to be effective for gene knockdown generally and on in vitro activity criteria, HSA4 (targeting exon 5) and HSA10 (targeting exon 7 in the 3′ UTR) were selected for further testing. We initially assessed HSA4 and HSA10 guide siRNA expression levels processed from the shRNAs in vitro, using northern blot analysis (Supplementary Material, Fig. S1 ). rAAV plasmids with the HSA4 and HSA10 hairpin expression cassettes were transfected into HEK293, cells and total RNA was isolated 48 h later. We compared northern blot results from transfection of rAAV plasmids containing an shRNA, a 5′ extended shRNA and a microRNA (miR) carrying the same HSA target sequences. Radioactively labeled ASO probes identified guide strand siRNAs produced from all three types of hairpins. RNAi hairpins expressed from miRNA templates are typically found at much lower levels than shRNAs, and therefore, the siRNAs produced from the miR hairpins are difficult to detect even with sensitive radioactive probes (29) . Because the miRNA-based shuttles generally have proven safe and effective at these expression levels as measured in vivo, we chose the mir-30-based RNAi hairpins for systemic RNAi therapeutic testing (43) . The rAAV6-HSARNAi vectors developed for in vivo testing also carried the reporter gene human placental alkaline phosphatase (hPLAP) for identification of transduced myofibers (Fig. 1B) .
Systemic administration of AAV6-HSA-RNAi vectors
The RNAi vectors were tested for the ability to silence the CUG staining of cryosections revealed widespread skeletal muscle transduction in tibialis anterior (TA), quadriceps and gastrocnemius muscles, although there was some variation within and between muscles as is typically seen for rAAV gene delivery ( Fig. 2A ) (38) . Quantitation of serum levels of the liver enzymes alanine transaminase (ALT) and aspartate aminotransferase (AST) at 3-4 weeks post-injection showed no elevation, a time when oversaturation of the RNAi pathway can result in liver damage (28, 44 previously shown to be necessary for decreasing myotonic discharges and reversing splicing defects (19, 24) . To verify the production and to estimate the number of artificial siRNAs made from the miRNA-based hairpins in rAAV6-HSA10-treated muscle tissue, we performed small RNA qPCR. Total RNA was analyzed by small RNA RT-qPCR specific for the predicted HSA10 guide siRNA. MicroRT (μRT) was performed using the total RNA samples from the TA muscles of the 8 week cohort of mice and a stem-loop primer with homology to the HSA10 guide siRNA (45) . DNA generated from the μRT reaction was used for small RNA qPCR using primers homologous to the stem-loop region and the HSA10 guide siRNA. These studies indicated that between 10 and 50 copies of the predicted guide strand were present in the treated muscles per ng of total RNA (Fig. 3B) .
Treatment of the HSA LR mice with rAAV6-HSA10 reduces myotonic discharges in muscle
Reduced levels of the Mbnl1 splicing factor in the HSA LR mice lead to misregulated alternative splicing of the muscle-specific chloride channel, Clcn1, resulting in loss of the chloride channel activity (12, 46) . The loss of chloride conductance causes repetitive action potentials, or myotonia, that are detected by electromyographic (EMG) techniques. HSA LR mice treated with rAAV6-HSA10 displayed a reduction in myotonia grade in the TA muscle with variation between individual mice tested at 8 weeks post-injection ( Splicing regulation is improved in the rAAV6-HSA10-treated HSA LR mice
Splicing defects in HSA LR and Mbnl1 knockout mice are highly concordant, and recapitulate many, but not all changes in human DM1 (11) . To assess RNAi effects on splicing regulation, we examined three exons that are regulated by Mbnl1 and strongly affected in DM1. Alternative splicing of Atp2α1 exon 22 switches from near complete inclusion in normal muscle to strong skipping in DM1 and HSA LR muscles. The TA muscles from the rAAV6-HSA10-treated HSA LR mice displayed on average 75 and 85% inclusion of exon 22 at 8 and 12 weeks post injection, respectively ( Fig. 5A ; P < 0.005). Clcn1 mRNA splicing was largely corrected, as indicated by a reduction in inclusion of exon 7a from 20 to 8%, a level approaching WT levels ( Fig. S3C ). To control for non-specific or vector related effects on the disease phenotype, we injected 4 × 10 12 vgs of a rAAV6 containing either the miRNA sequence for targeting bacterial lacZ mRNA (βgal) or only the hPLAP gene without an RNAi hairpin sequence (47) . There was not a significant difference in the percent exclusion of exon 22 of the Atp2α1 mRNA in the HSA LR TA muscles using either control vector compared with untreated mice (Fig. 5D ). In addition, splicing changes were not significant with the rAAV6-HSA4 vector, possibly from lower activity of the HSA4 hairpin, because expression of the HSA4 miR was comparable to HSA10 miR in vitro (Supplementary Material, Figs S1 and S3D). The lack of Atp2α1 mRNA splicing changes with rAAV6-HSA4 treatment was consistent with the inability of this vector to reduce myotonia in these mice.
To test whether the phenotypic improvement correlated with vector dose additional HSA LR , mice were examined that had received a lower dose of rAAV6-HSA10. Tail vein injection of 2 × 10 12 vgs resulted in no change in myotonia (data not shown), reduced hPLAP staining and limited correction of Atp2α1 and Clcn1 mRNA splicing (Supplementary Material, Fig. S4 ) (34, 47) . Splicing assays showed a trend toward reversal to the adult isoform between the 8 and 12 week time points post treatment that reached significance at 25% reduction of exon 7a inclusion for Clcn1 mRNA splicing. The lower vector dose resulted in less reduction of the Non-linear regression was performed based on Gaussian distribution with a least squares (ordinary) fit (n = 6 TA total cryosections from 3 mice each treated, untreated, and control mice). All mice received tail vein injections of 4 × 10 12 vg at 4 weeks of age and were analyzed at 12 weeks of age (8 weeks post injection). Scale bars: 100 μm.
neonatal mRNA isoforms compared with higher rAAV6-HSA10 dose (Fig. 5) , suggesting a dose dependency of the effect. The mitigation of the skeletal muscle disease in the HSA LR mice at the 2-fold lower dose is supported by evidence of a threshold effect near the level of the 2 × 10 12 vg dose for rAAV6 muscle transduction with systemic delivery in mice (48) .
Nuclear foci reduction and Mbnl1 nuclear redistribution in rAAV6 HSA10-treated HSA LR mice RNA FISH detection of CUG exp HSA transcripts identified numerous bright nuclear foci in the TA of the HSA LR mice (Fig. 6A) . A significant decrease in the number of foci was observed in the rAAV6-HSA10-treated mouse muscles (n = 7) at 8 week post injection compared with untreated HSA LR mice ( Fig. 6B ; P < 0.0001; n = 4 fields at 20 × magnification; n = 3 HSA LR ). We also observed a significantly more diffuse pattern of Mbnl localization in the nuclei of treated muscle cryosections with immunohistochemical detection of Mbnl1 immunofluorescence compared with the bright, punctate immunofluorescent signals in the untreated HSA LR muscles (Fig. 6C) . The transition to a more diffuse nuclear pattern of staining shows a normalization of Mbnl1 localization that is more similar to its localization in WT mice.
RNA biomarker levels are downregulated in the rAAV6-HSA10-treated HSA LR mice
To determine whether treatment led to a change in the expression levels of mRNAs associated with disease pathology, we examined the expression of two genes, Atp1β4 and Mustn1, previously shown to be upregulated in the HSA LR mice (Supplementary Material, Fig. S5 ) (24) . RT-qPCR quantitation of the level of these transcripts, compared with WT FVB mice, showed an approximately 2-fold relative decrease compared with the levels in untreated HSA LR mice at 8 weeks post injection ( p < 0.0001).
Discussion
Therapeutic RNAi has shown great promise for treating diseases of the liver, brain and eye, where changes in gene expression can ameliorate disease (49, 50) . Previous studies from our laboratory and others have demonstrated the potential for success of muscle disease RNAi therapy. We now add to this list the potential for systemic RNAi therapy of muscle disease, regardless of the intracellular localization (nuclear or cytoplasmic) of the target mRNA. Unlike most mRNA targeting studies where the mRNA is cytoplasmic, there is compelling evidence that the majority of the CUG exp RNA is located in the nucleus both in DM1 and the HSA LR mouse model (7, 18, 19) . Early DMPK mRNA silencing studies in vitro using lentivirus delivery of DMPK shRNA expression cassettes were successful in reducing the DMPK CUG exp mRNA and supported development of this approach as a bodywide treatment for DM1. This was the first study suggesting that therapeutic RNAi could work on a nuclear target, and soon after Robb et al. (36) reported RNAi activity could be targeted to the nuclear RNAs 7SL and U6 snRNA. Controversy regarding the possibility of RNAi functioning in the nucleus has been longstanding, and originated from studies showing that intron targeting was ineffective and that RNAi factors had a predominantly cytoplasmic localization (51) . However, mounting evidence from studies in mammalian cells now supports the activity of RNAi in the nucleus (52) . Careful cell fractionation studies indicate that Ago2 and other RNAi factors are present in the nucleus in multiprotein complexes (53) (54) (55) . Nuclear Dicer and Ago2 isolated from nuclei are catalytic activity, and nuclear Ago2 associates with endogenous miRNAs. These data refute the early assumption that RNAi functioned only in the cytoplasm. Despite the compelling evidence for RNAi in the nucleus, it is still possible that the pathogenic population of HSA CUG exp mRNA is found in the cytoplasm as a minor population and is targeted by the therapeutic RNAi, whereas the nuclear accumulated HSA CUG exp mRNA is gradually degraded over time by other mechanisms (19) . Based on the early reports of RNAi activity in nuclei, we sought to develop a bodywide delivery system in a relevant disease mouse model that could lead to a clinical RNAi therapy for DM1. Relative quantitation, ΔΔCt, was determined from comparing HSA mRNA levels to non-transgenic WT mice, with normalization to an endogenous control in each mouse (one-way ANOVA statistical methods with Dunnett's multiple comparison test of all samples to the control HSA LR ; P < 0.01;±SD; n = 7 treated and three WT and three untreated HSA LR mice). (B) Absolute quantitation of levels of HSA10 miRNA were determined with small Taqman qPCR (stem-loop PCR) and compared with small Taqman qPCR from an RT that was spiked with known quantities of synthetic HSA10 siRNA. Gapdh expression was used as an endogenous control to relate quantitation to genomic DNA copy number. All qPCRs were performed in triplicate; n = 7 treated and 3 untreated HSA LR mice. (58, 59 ). However, partial knockdown of both the mutant and non-mutant alleles is predicted to significantly reduce the burden of the CUG EXP mRNA and may not interfere with the function of DMPK, because knockout of the mouse gene leads to only mild phenotypic effects in aged animals (60) . Experimental evidence also supports the protective function of CUG exp mRNA foci, which may allow tolerance of some mutant mRNA without manifestation of disease (61) (62) (63) . Since discovery of the DNA repeat expansion basis of DM1 and deciphering the toxic RNA gain-of-function mechanism several approaches for therapy development have been undertaken. These include methods to interfere with protein binding of toxic CUG exp repeat RNA (64, 65) , overexpression of MBNL1 (66), drugs that alter signaling (67), and both synthetic and expressed ASOs (19, 22, 24) . Of the synthetic ASOs, the most effective tested in mice are the MOE-gapmers (2′-O-methoxyethyl end-modified ASOs) that are substrates for RNase H cleavage when bound to DMPK mRNA outside of the repeat region (24). Because both RNase H and DMPK CUG exp mRNA are predominantly nuclear, it may be possible to deliver low levels of the MOE-gapmers for efficacy that was achieved in mice, thereby reducing the chance of adverse treatment reactions. However, most of the ASO and protein drug delivery will require continuous treatment and could produce toxicities with repeated dosing. In contrast, rAAVmediated delivery of genes has progressed beyond testing in mice to large animal muscular dystrophy models, the canine model of Duchenne muscular dystrophy (CXMD) and the X-linked myotubular myopathy model (XLMTM) (68) (69) (70) . rAAV has also shown success with a single application in the brain of nonhuman primates for Huntington's disease and has proven safe and effective in a growing number of cases in humans, such as Leber's congenital amaurosis and lipoprotein lipase deficiency (33, 71) . Because the HSA LR mouse model does not recapitulate the multisystem aspects of DM1, more work will have to be done to address delivery concerns, especially for disease effects in the CNS and gastrointestinal tract. One option might be to combine other serotypes of rAAV for therapeutic RNAi delivery that show different tissue biodistributions with the predominantly muscle tropic rAAV6 or use another serotype altogether (72,73).
There are over 100 isolated serotypes of rAAV that could be used to deliver RNAi expression cassettes to multiple tissues (32). Our results using rAAV delivery of therapeutic RNAi to reverse DM1 disease features in the HSA LR mouse suggests that further vector development for evaluation in emerging DMPK mouse models will help advance this approach toward clinical testing.
Methods

Plasmids for HSA reporter and RNAi expression cassettes
Plasmid pLI-ACTA was constructed by inserting a firefly luciferase SmaI/XbaI fragment from pGL3-Basic (Promega Corporation, Madison, WI, USA) into the EcoRV/NheI sites of pIRESneo3 HSA LR PCR samples are indicated as LR and wild-type FVB as WT. P-values were calculated using a Student's t-test; error bars ± SD.
(Clontech Laboratories, Mountain View, CA, USA) to make pLIN (kind gift of Chao-Zhong Song and George Stamatoyannopoulos, University of Washington, Seattle, WA, USA). The neo gene was removed from pLIN by simultaneous restriction endonuclease cleavage with SmaI and XbaI and the HSA gene (ACTA1) was removed from pCMV6-XL4-ACTA1 human cDNA clone with NotI cutting (Origene, Rockville, MD, USA). The ACTA1 NotI fragment was blunt-ended and ligated to the pLI SmaI/XbaI cut vector to make pLI-ACTA containing the firefly luciferase gene, an IVS, an IRES from ECMV and the ACTA1 cDNA. The mouse U6-siβgal control plasmid (gift of Beverly Davidson, University of Iowa) was described previously and the miRNA version constructed for this study, mU6miRβgal, was based on the same lacZ gene target sequence from Escherichia coli (bp 1152−1172). The βgal sequence was incorporated into the miR30 shuttle as described for artificial miRNA vectors below (31) . All original HSA shRNAs were made using overlapping oligonucleotides for mU6 5′ sequences and shRNA sequences incorporated in the 3′ oligonucleotide for PCR generation from pAdmU6. Sequences of the HSA miR DNA, corresponding to the siRNA predicted, were HSA4 5′ ctatcgagcacggcatcatcac 3′ (bold are additions from original shRNA) starting at position 320 of the HSA mRNA and HSA10 5′ ctcaggacgacgaatcttctca 3′ starting at position 1269 of the HSA mRNA. These sequences were embedded in the miR30 scaffold (74) with XhoI and SpeI sites added for cloning into the XhoI/ XbaI sites of pCR Blunt II TOPO (Invitrogen, Carlsbad, CA, USA) containing an the mU6 promoter and RNA Pol III T termination sequence as described previously (75) . An EcoR I fragment containing the miR30-based expression cassette was blunt-ended and ligated into the 5′ SnaB I site of the rAAV2 plasmid pARAP4 (kind gift of Dusty Miller, FHCRC) containing the reporter gene RSV-hPLAP. The 5′ extended versions of the HSA4, HSA10 and LacZ/bgal shRNA hairpins had an additional 27 nt as described previously (28, 57) . All RNAi target sequences were chosen based on basic shRNA design rules from the RNAi Consortium of the Broad Institute, Cambridge, MA, USA, based on rules established by Tuschl and co-workers (39-41). MiR30-based hairpin sequences were analyzed for proper folding for Drosha and Dicer recognition with Michael Zuker's UNAfold program (IDT, Coralville, IA, USA), checked for homology of passenger or guide strands to other known genes, and analyzed for seed sequence homology using the siRNA Seed Locator (Thermo Scientific; Fisher, Pittsburg, PA, USA).
Virus preparation
rAAV6 was prepared and tittered by Southern blot analysis for viral genomes as described (48) . Typical titers were 3 × 10 13 vg/ml from 30 roller bottles. The RNAi expression cassettes sequences were confirmed with the difficult to sequence protocol (RNAi hairpin; Genewiz, Seattle, WA, USA).
Luciferase assays
HSA shRNA plasmids or control plasmids, with either mU6 alone or mU6sibgal, were cotransfected with pLI-ACTA reporter plasmid into COS-1 cells using the FuGENE 6 reagent (Promega, Mountain View, CA, USA) in a 3:1 ratio to DNA, 500 ng total per well of 12-well culture dish. All of the 16 HSA shRNA plasmids were tested in each experiment and repeated in six different experiments performed on different days with luciferase assays performed in triplicate. Cell lysates were prepared 48 h after transfection and assayed on a single well Berthold luminometer using the Luciferase Assay System (Promega). Results from HSA shRNA and reporter transfection assays were normalized to the mU6 or mU6siβgal plasmid.
Animals, injections, blood and tissue collection
All animal experiments were approved by the Institutional Animal Care and Use Committee of the University of Washington. All mice used in these studies were of the FVB/N strain (wildtype/genetic background strain for HSA LR ) or human α-skeletal muscle actin long-repeat (HSA LR ) homozygous transgenic, line after injections, and tissues were collected for analysis. For splicing analysis and real-time PCR, tissues were flash frozen in liquid nitrogen. For histology, histochemistry, immunofluorescence and FISH, tissues were embedded in OCT and frozen in liquid nitrogen-cooled isopentane.
Electromyography
Needle EMG study was performed using a Viking Quest electromyograph (Nicolet, Madison, WI, USA). Mice were anesthetized with 5% isofluorane gas with 100% O 2 delivered at 2.5 l/min in an induction chamber, then maintained under anesthesia with a cone facemask connected to a coaxial circuit during the EMG procedure. The quadriceps or TA muscles were sampled in the proximal, middle and distal regions of the muscle belly using a 25-gauge concentric needle electrode after ethanol sterilization of the area. A steel needle electrode (Dantec, Copenhagen, Denmark) was placed subcutaneously as a ground electrode in the muscle about 1 cm proximal to the recording site. EMG analysis of myotonic discharges was performed by a blinded examiner as described previously (76) . Myotonic discharges were graded 0, indicating no myotonic discharge; 1, occasional myotonic discharge (less than 50% of needle electrode insertions); 2, myotonic discharge (greater than 50% of needle electrode insertions) and 3, myotonic discharge with nearly every insertion.
Histology and histochemistry
Transverse frozen sections (10 μm) were cut from OCT-embedded tissues. For basic histology analysis, sections were fixed in methanol and stained with H&E/Phloxine using a standard protocol. For analysis of transduction efficiency, sections were stained for hPLAP activity as previously described with slight modifications (34) . Briefly, sections were fixed in ice cold 4% PFA/PBS for 10 min, washed with PBS, incubated at 67°C for 90 min in PBS to deactivate endogenous alkaline phosphatases, incubated in AP wash buffer (100 m Tris-HCl pH 9.5, 100 m NaCl, 10 m MgCl 2 ) for 10 min at room temperature, and stained with the BCIP/NBT substrate (Fast BCIP/NBT tablets from SigmaAldrich) for 40 min at room temperature. Sections were then washed with PBS, dehydrated and mounted with Permount. Stained sections were analyzed and photographed using a Nikon Eclipse E1000 microscope.
Fluorescence in situ hybridization
Localization of CUG exp RNA by fluorescence in situ hybridization (FISH) was carried out as previously described with slight modifications (77) . Briefly, 10 mm frozen sections of the TA and quadriceps muscles were fixed in 3% PFA/PBS for 15 min at room temperature, washed with PBS and permeabilized with 0.5% Triton X-100/PBS for 5 min at room temperature. Sections were then prehybridized in 30% formamide for 10 min at room temperature, hybridized with the 5′ Texas red 2-O-methyl-CAG RNA probe (CAGCAGCAGCAGCAGCAGCA) in 30% formamide for 2 h at 37°C in the dark, post-hybridized in 30% formamide for 30 min at 42°C, incubated in 1× SSC for 30 min at room temperature, washed with PBS, incubated with FITC-labeled wheat germ agglutinin for 45 min at room temperature to stain cell membranes, washed with PBS and mounted with DAPI-containing ProLong Gold (Life Technologies) mounting media. Images were acquired using the Leica SP5 confocal microscope at the University of Washington Biology Imaging Facility. Muscle fibers were manually selected and their cross-sectional areas were calculated based on a micron to pixel conversion using the Record Measurement function in Adobe Photoshop. The number of RNA foci was counted in projection images with the red channel intensity set to a constant min and max intensity. High intensity foci (minimum set to 0 and 200 pixel intensities, respectively) were counted from four different fields for each sample taken at 20× magnification on a Leica SP5 confocal microscope at the University of Washington Biology Imaging Facility. CSA counts were taken of 2, 10 μm-thick, cross sections of TA muscle from separate regions of TAs isolated from three different mice for FVB, HSA LR , or treated mice at 20× magnification on a Leica SP5 confocal microscope. Boundaries were drawn around fibers and enclosed surface areas were determined using the Adobe Photoshop software measure function and pixel-size information from the confocal images. A frequency distribution histogram was generated using GraphPad Prism software. Curves were derived from nonlinear regression using a least squares fit in the Gaussian distribution.
Immunofluorescence
Localization of MBNL1 by immunofluorescence was carried out as previously described with minor modifications (11) . Briefly, 10 mm frozen sections of the TA and quadriceps muscles were fixed in 3% PFA/PBS for 15 min, washed with PBS, permeabilized with 0.5% Triton X-100/PBS for 5 min and blocked in 5% normal goat serum in PBS for 30 min, all at room temperature. Sections were then incubated with the primary antibody (MBNL A2764, 1:10 000 in 1% BSA/PBS) overnight at 4°C, washed with PBS, incubated with the secondary antibody (goat anti-rabbit Alexa488, 1:400 in PBS) in the dark for 45 min at room temperature, washed with PBS and mounted with DAPI-containing ProLong Gold mounting media (Life Technologies). Images were acquired using a Leica SP5 confocal microscope at the University of Washington Biology Imaging Facility.
RT-PCR analysis of alternative splicing
Splicing analysis for Clcn1, Atp2α1 and m-Ttn was carried out as previously described (11) . Briefly, RNA was isolated from flash frozen tissues using the mirVana miRNA Isolation Kit (Life Technologies). cDNA was synthesized using oligo (dT) plus random hexamer primers and treated with RNase H at 37°C for 35 min. PCR amplification was carried out for 24 cycles using the following primers: ClC-1 forward: 5′ TGAAGGAATACCTCACACTCAAGG 3′, reverse: 5′ CACGGAACACAAAGGCACTGAATGT 3′, Atp2α1 forward: 5′ GCTCATGGTCCTCAAGATCTCAC 3′, R-5′ GGGTCAGTGCC TCAGCTTTG 3′ and m-Ttn forward: 5′ GTGTGAGTCGCTCCAG AAACG 3′, R: 5′ CCACCACAGGACCATGTTATTTC 3′. PCR products were resolved on agarose gels, stained with SYBR Green and scanned with a Molecular Dynamics Storm 860 scanner. Band intensities were quantified by densitometry using GE Healthcare Life Sciences ImageQuant TL 8.1 software.
Small RNA Northern analysis
Total RNA was isolated from rAAV RNAi plasmid-transfected HEK293 cells using the mirVana miRNA Isolation kit (Life Technologies), 25 μg of total RNA per sample was run on Novex 15% TBE-Urea gels with 300 pg and 30 pg of sense or guide equivalent oligonucleotide per RNAi plasmid run concurrently as positive controls. Gels were run in RNase-free 1 × TBE at 100 V for 3-4 h, then stained with ethidium bromide and photographed as a reference for equivalent loading and migration of total RNA. PNK (New England Biolabs) and unincorporated 32 P was subsequently removed with G25 spin columns (GE Healthcare). Probes were then heat denatured and added to hybridization buffer and the RNA-bound membrane for 16 h hybridization at 32°C. All membranes were washed for 15 min, followed by three washes for 5 min each in 2× SSC/0.5% SDS at 32°C. Membranes were wrapped in one layer of plastic wrap and sandwiched exposed simultaneously to a phosphor screen and BioMax XAR film (Kodak). Film and phosphor screens were exposed from approximately 7-10 days at room temperature before either developing the film or scanning the phosphor screen on a Storm 860 Scanner (GE Healthcare).
Real-time PCR assays
RNA for all real-time PCR assays was isolated as for splicing analysis. Relative expression levels of ACTA1 were determined by hydrolysis probe reactions and normalized to 18s rRNA reference gene (24) . cDNA was synthesized using oligo(dT) primers and qPCR was performed under standard reaction conditions on an ABI 7500. Following primer/probe set was used: Forward: 5′ GACGAGGCTCAGAGCAAGAGA 3′, reverse: 5′ TGA TGATGCCGTGCTCGATA 3′, probe: 6-FAM-5′ CCTGACCCTGAAGT AC 3′. Relative expression levels of biomarkers Mustn1 and Atp1β4, relative to Ywhaz were determined using the SYBR Green method. cDNA was synthesized as for ACTA1 and qPCR was performed using the Power SYBR Green PCR Master Mix (Life Technologies, Grand Island, NY, USA). Following primers were used (all designed to span exon junctions): Mustn1-forward: GCCAAGAACCAGGACATCAAGTC, Mustn1-reverse: 5′ CTCAAA GACTGTCTCGGTGCCT 3′ (MP208457, NM_181390), Atp1β4-forward: 5′ AGTCCGCTTCTTTTGACCTCCG 3′, Atp1β4-reverse: 5′ AGGCAC TGCTTGGTTCTTCACC 3′ (MP201058, NM_133690), Ywhaz-Fwd: 5′ CTTCCTGCAGCCAGAAGC 3′, Ywhaz-Rev: 5′ GGTTTCCTCCAA TCACTAGCC 3′ (IDT). Absolute levels of processed mature miRNA were determined using a custom TaqMan Small RNA Assay (Life Technologies). cDNA was synthesized using the small RNA target-specific stem-loop RT primer and reagents from the TaqMan MicroRNA reverse transcription (μRT) kit (Life Technologies). qPCR was performed using the TaqMan small RNA assay (μRT-qPCR assay, Life Technologies) along with TaqMan Universal PCR Master Mix II, no UNG (Life Technologies) under standard product protocol conditions. Efficiency of the reaction was 83%. Standards for absolute quantitation were prepared by adding a known amount of the HSA10 oligonucleotide corresponding to the guide siRNA to FVB control mouse tissue homogenate during RNA isolation.
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